Clinical trial Recruiting at 2 sites Observational Ages 18 and up

Identifying biomarkers for lung cancer immunotherapy

Official title: Genomic Analysis to Identify a Predictive Biomarker for Immunotherapy

Run by Samsung Medical Center · NCT03578185 · Data updated 2026-11-12

This study is trying to find specific markers in lung cancer patients' samples to see if they can predict how well immunotherapy treatments will work for them.

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment2000 (estimated)
SponsorSamsung Medical Center
Academic / other
Drugs / interventionsimmunotherapy, chemotherapy, radiation
Locations3 sites (Seoul, Gangnam-gu and 2 other locations)
StatusRecruiting
StartedApril 11, 2018
Main results expectedDecember 31, 2030
Study endsDecember 31, 2030
Registry record updatedAugust 12, 2026
Trial IDNCT03578185 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults aged 18 and older with histologically confirmed lung cancer who have been treated with immune checkpoint inhibitors.

Probably not a fit

Patients who have not been treated with immune checkpoint inhibitors or those under 18 years old may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to identify predictive biomarkers for immunotherapy in lung cancer patients by analyzing samples such as tumor tissue, blood, and fecal material from individuals treated with immune checkpoint inhibitors. The study will collect clinical data, including demographics, treatment history, and histologic information, to correlate with the biomarker findings. Informed consent is waived for samples donated from other clinical trials, allowing for a broader analysis of existing data.

Why it matters

Potential benefit: If successful, this study could lead to more personalized and effective immunotherapy treatments for lung cancer patients.

How similar studies have gone: Other studies have shown promise in identifying biomarkers for immunotherapy, suggesting that this approach may yield valuable insights.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. aged above or equal to 18
2. Histologically confirmed lung cancer patients
3. Patient treated with immune checkpoint inhibitor

Exculsion Criteria:

NA

Where it's running

  • Samsung Medical Center
    Seoul, Gangnam-gu, South Korea
    Recruiting
  • Seoul National University Hospital
    Seoul, Joungro-gu, South Korea
    Recruiting
  • Asan Medical Center
    Seoul, Songpa-gu, South Korea
    Not yet recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.